Anaplastic Lymphoma Kinase (ALK) Inhibitors (SJ-08-0025)



Technology Name
(St. Jude Reference #)
Anaplastic Lymphoma Kinase (ALK) Inhibitors
(SJ-08-0025)
Description ALK is a receptor tyrosine kinase that has been associated with several different cancers.  Researchers at St. Jude have designed, synthesized and tested a novel kinase inhibitor template. Compounds based on this core template demonstrate activity and selectivity for ALK, indicating they are suitable starting points for the development of more active lead-like inhibitors.
Keywords NPM-ALK, kinase, lymphoma, cancer, inhibitor
Granted Patents or Published Applications Pending provisional application
Related Scientific References Slavish P. Jake et al; Design and synthesis of a novel tyrosine kinase inhibitor template; Bioorganic & Medicinal Chemistry 17 (2009) 3308 – 3316.
Licensing Opportunities We are currently seeking licensing opportunities in all fields for this technology.

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: September 2009